Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in 110 Metformin-treated Patients with Type 2 Diabetes
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 2 diabetes mellitus (T2DM) treated with stable dose of metformin \> or = to 1500mg/day as monotherapy for at least 8 weeks
Hemoglobin A1c (HbA1c) 7% to 10% at screening
Body mass index (BMI) \< or = to 45 kg/m2
You may not be if
History of taking antihyperglycemic therapy other than metformin or metformin extended release (XR) during the 8 weeks prior to screening
History of taking a dipeptidyl peptidase-4 (DPP-4) inhibitor or pramlintide during 12 weeks prior to screening
History of potent, inhaled or intrapulmonary steroids 3 months prior to screening or during the study
History of prescription or over the counter weight loss medication during 3 months prior to screening
Previous exposure to exenatide or any glucagon-like peptide-1 (GLP-1) receptor agonist during 6 months prior to screening
